학술논문
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged =18 Years with Immunocompromising Conditions -- VISION Network, September 2023-February 2024.
Document Type
Article
Author
Link-Gelles, Ruth; Rowley, Elizabeth A. K.; DeSilva, Malini B.; Dascomb, Kristin; Irving, Stephanie A.; Klein, Nicola P.; Grannis, Shaun J.; Ong, Toan C.; Weber, Zachary A.; Fleming-Dutra, Katherine E.; McEvoy, Charlene E.; Akinsete, Omobosola; Bride, Daniel; Sheffield, Tamara; Naleway, Allison L.; Zerbo, Ousseny; Fireman, Bruce; Hansen, John; Goddard, Kristin; Dixon, Brian E.
Source
Subject
*COVID-19 vaccines
*HOSPITAL care
*IMMUNOCOMPROMISED patients
*VACCINATION
*
*
*
Language
ISSN
0149-2195
Abstract
In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged =6 months to prevent COVID-19, including severe disease. As with past COVID-19 vaccines, additional doses may be considered for persons with immunocompromising conditions, who are at higher risk for severe COVID-19 and might have decreased response to vaccination. In this analysis, vaccine effectiveness (VE) of an updated COVID-19 vaccine dose against COVID-19-associated hospitalization was evaluated during September 2023-February 2024 using data from the VISION VE network. Among adults aged =18 years with immunocompromising conditions, VE against COVID-19-associated hospitalization was 38% in the 7-59 days after receipt of an updated vaccine dose and 34% in the 60-119 days after receipt of an updated dose. Few persons (18%) in this high-risk study population had received updated COVID-19 vaccine. All persons aged =6 months should receive updated 2023-2024 COVID-19 vaccination; persons with immunocompromising conditions may get additional updated COVID-19 vaccine doses =2 months after the last recommended COVID-19 vaccine. [ABSTRACT FROM AUTHOR]